How does controlled lysosomal membrane permeabilization induce autophagy without triggering cell death?

Therapeutic Hypotheses: Trehalose-Induced LMP and Paradoxical Autophagy Enhancement

Hypothesis 1: Limited Calcium Release Without Sufficient Cathepsin Efflux

Mechanism: Trehalose induces selective lysosomal permeabilization that preferentially releases Ca²⁺ without complete cathepsin efflux. Lysosomal Ca²⁺ release activates calcineurin, leading to TFEB nuclear translocation and autophagy gene transcription, while insufficient cytosolic cathepsin activity fails to trigger apoptotic cascades.

Target: Lysosomal calcium channel (MCOLN1/TRPML1), calcineurin/NFAT pathway

Supporting Evidence:

• TRPML1-mediated lysosomal Ca²⁺ release activates calcineurin and TFEB nuclear translocation (PMID: 27807044)
• Partial LMP preferentially releases small molecules (Ca²⁺, ATP) before larger hydrolases (PMID: 23645775)
• Trehalose osmotic effects may selectively open lysosomal Ca²⁺ channels

Confidence: 0.72

Hypothesis 2: Differential Calpain-Mediated Cleavage of Apoptotic vs. Autophagic Substrates

Mechanism: Transient cathepsin release activates cytosolic calpains, which preferentially cleave pro-apoptotic proteins (BID, BAX) into inactive fragments, while autophagy machinery proteins remain intact or are cleaved into activating forms. This creates a temporary "apoptosis-proofed" state that permits autophagic flux.

Target: CAPN1/CAPN2 (calpains), BID, BAX, AMPK

Supporting Evidence:

• Calpains cleave BID into pro-survival fragments that antagonize full-length BID function (PMID: 15068671)
• Limited calpain activation can cleave BAX into an inactive form (PMID: 16103217)
• Calpain-mediated AMPK activation links Ca²⁺ signaling to autophagy initiation (PMID: 21971070)

Confidence: 0.65

Hypothesis 3: BAG3-Mediated Hsp70 Substrate Redistribution

Mechanism: Trehalose induces Hsp70 and BAG3 expression, redirecting Hsp70 chaperone activity from inhibiting autophagy receptors (e.g., p62/SQSTM1 sequestration) toward maintaining lysosomal membrane integrity and preventing cytochrome c release. BAG3 simultaneously promotes autophagosome-lysosome fusion while inhibiting apoptosis initiation.

Target: HSPA1A/Hsp70, BAG3, p62, cytochrome c

Supporting Evidence:

• BAG3 redirects Hsp70 from proteasomal to autophagic degradation (PMID: 25983032)
• Hsp70 prevents Bax translocation to mitochondria and cytochrome c release (PMID: 12082527)
• Trehalose upregulates Hsp70 as a general stress response (PMID: 21654180)

Confidence: 0.68

Hypothesis 4: Cathepsin-Dependent Processing of Pro-Drug Enzymes into Autophagy Activators

Mechanism: Trehalose-induced LMP releases cathepsin D, which specifically cleaves a cytosolic substrate (potentially pro-CTSD or an unidentified regulatory protein) into fragments that activate autophagy. These same fragments may degrade inhibitory proteins of apoptosis, creating parallel beneficial outcomes.

Target: CTSD (cathepsin D), unidentified substrate "X"

Supporting Evidence:

• Cathepsin D can cleave and activate pro-autophagy proteins (PMID: 23716583)
• Cathepsin D cleaves Bid into pro-survival fragments at different sites than caspases (PMID: 14517278)
• Cathepsin D release correlates with autophagy in trehalose models (PMID: 30335591)

Confidence: 0.58

Hypothesis 5: TFEB-Dependent Transcription of Lysosomal Biogenesis Genes Reduces LMP Toxicity Threshold

Mechanism: TFEB activation by trehalose increases lysosomal biogenesis, expanding the lysosomal population. This creates a higher threshold for apoptosis—more lysosomes must permeabilize to release sufficient cathepsins for mitochondrial outer membrane permeabilization (MOMP), while the increased lysosomal mass accelerates autophagosomal degradation.

Target: TFEB (TFE3), lysosomal V-ATPase, CTSD, ATP6V1H

Supporting Evidence:

• TFEB overexpression increases lysosome number and protects against proteotoxic stress (PMID: 29437794)
• Increased V-ATPase activity enhances autophagic flux (PMID: 26387543)
• Trehalose activates TFEB nuclear translocation (PMID: 30335591)

Confidence: 0.74

Hypothesis 6: Selective PI3P Generation at Damaged Lysosomes Promotes Membrane Repair

Mechanism: Trehalose-induced LMP creates "damaged lysosome" signals that selectively recruit PtdIns3P-generating machinery (PI3KC3 complex II) to initiate autophagosome formation at lysosomal membranes. This PI3P generation simultaneously recruits repair machinery (ESCRT-III) while excluding apoptotic initiators (Apaf-1, procaspase-9), directing the response toward repair rather than death.

Target: PIK3C3/VPS34, PIK3R4/VPS15, CHMP2A (ESCRT-III), Apaf-1

Supporting Evidence:

• Damaged lysosomes recruit VPS34 complexes to generate PI3P for autophagy initiation (PMID: 29311636)
• ESCRT-III machinery repairs permeabilized lysosomes (PMID: 29274069)
• PIK3C3 complex II localizes specifically to damaged organelles (PMID: 30606815)

Confidence: 0.62

Hypothesis 7: Metabolic Reprogramming Toward Glyceraldehyde-3-Phosphate Dehydrogenase Inhibition of Apoptosis

Mechanism: Trehalose metabolism generates intermediates (particularly GAPDH activity modulators) that inhibit GAPDH nuclear translocation required for apoptosis. Meanwhile, trehalose-derived metabolites support ATP production needed for autophagy, creating a metabolic switch favoring survival.

Target: GAPDH, HK2 (hexokinase II), VDAC1

Supporting Evidence:

• GAPDH nuclear translocation triggers apoptosis in neurodegeneration models (PMID: 28877451)
• Trehalose metabolism engages the pentose phosphate pathway (PMID: 28122321)
• Hexokinase II binding to VDAC1 prevents apoptosis initiation (PMID: 29478836)

Confidence: 0.55

Summary Table

| # | Hypothesis | Primary Target | Confidence |
|---|------------|----------------|------------|
| 1 | Limited Ca²⁺ release without cathepsin efflux | TRPML1/calcineurin | 0.72 |
| 2 | Differential calpain cleavage | CAPN1/2 | 0.65 |
| 3 | BAG3-Hsp70 redistribution | HSPA1A/BAG3 | 0.68 |
| 4 | Cathepsin D substrate processing | CTSD/"substrate X" | 0.58 |
| 5 | TFEB-induced lysosome biogenesis | TFEB/TFE3 | 0.74 |
| 6 | PI3P generation at damaged lysosomes | PIK3C3/VPS34 | 0.62 |
| 7 | Metabolic reprogramming/GAPDH inhibition | GAPDH/HK2 | 0.55 | Recommended Priority Investigation: Hypothesis 1 (Ca²⁺ vs. cathepsin kinetics) and Hypothesis 5 (TFEB-driven lysosome biogenesis) represent the most tractable approaches with available tools and directly address the mechanistic paradox. Combined temporal analysis of Ca²⁺ release, cathepsin activity, and TFEB nuclear translocation using high-content imaging would rapidly discriminate between these models.

Critical Evaluation of Trehalose-LMP Paradox Hypotheses

Executive Summary

The hypotheses address an important paradox: why controlled lysosomal membrane permeabilization (LMP) by trehalose promotes autophagy rather than apoptosis. However, several hypotheses contain logical inconsistencies, mechanistic gaps, or rely on unestablished concepts. The critical assessment below revises confidence scores based on falsifiability and evidence quality.

Hypothesis 1: Limited Calcium Release Without Sufficient Cathepsin Efflux

Weak Links

Mechanistic selectivity is unexplained. The hypothesis assumes trehalose causes "selective" LMP that releases Ca²⁺ before cathepsins, but provides no mechanism for this selectivity. Is trehalose acting as a channel, osmotic agent, or membrane disruptant? The biophysics of selective LMP remain unspecified. Partial LMP kinetics have been described for some interventions (e.g., siramesine), but not for disaccharides.

TRPML1 pharmacology is misrepresented. The cited evidence (PMID: 27807044) shows TRPML1 activation promotes TFEB nuclear translocation, but TRPML1 is primarily characterized as an Fe²⁺/Zn²⁺ channel with lower Ca²⁺ permeability than previously thought (PMID: 29374143). Trehalose is not a known TRPML1 agonist—the osmotic mechanism for selective channel opening is speculative.

Counter-Evidence

• Lysosomal Ca²⁺ stores are released primarily via MCOLN1 (TRPML1) or cyclic ADP-ribose channels, but Ca²⁺ release typically occurs after membrane permeabilization, not as a precursor event.
• The "small molecule first" hierarchy for LMP (PMID: 23645775) is derived from osmotic stress models—not trehalose. Trehalose-induced LMP may follow different kinetics.
• If Ca²⁺ release alone activates TFEB, why doesn't any Ca²⁺-mobilizing agent (thapsigargin, ionomycin) produce the same protective autophagic response?

Falsifying Experiments

Revised Confidence: 0.45 (down from 0.72)

The selectivity mechanism is the critical weakness. Without an explanation for why trehalose causes selective vs. complete LMP, the hypothesis is incomplete.

Hypothesis 2: Differential Calpain-Mediated Cleavage

Weak Links

Core logical flaw: BID cleavage is pro-apoptotic. The cited reference (PMID: 15068671) is misrepresented. Calpain cleavage of BID generates truncated BID (tBID) at a different site than caspase-8, but tBID retains pro-apoptotic activity—it translocates to mitochondria and induces MOMP. There is no established evidence that calpain-cleaved BID is "pro-survival." The claim directly contradicts the literature.

Calpain is a death signal, not a survival signal. Calpain activation is consistently associated with necrotic and apoptotic cell death in neuronal models. The hypothesis proposes calpain activation as protective, which lacks precedent.

Autophagy machinery cleavage is non-specific. The claim that calpains cleave "AMPK, ULK1 into activating forms" is imprecise. ULK1 cleavage products are not canonical activators of autophagy.

Counter-Evidence

• Calpain inhibitors (ALLN, calpeptin) are neuroprotective in most models, not toxic. If calpain activity is required for trehalose's protective effect, calpain inhibitors should block protection—contradicting the literature.
• BAX cleavage by calpains (PMID: 16103217) generates a fragment that may be inactive, but BAX-independent apoptotic pathways (calpain-mediated caspase-12 activation, direct caspase-7 cleavage) remain viable.

Falsifying Experiments

Revised Confidence: 0.30 (down from 0.65)

The pro-survival BID cleavage claim is factually incorrect. Even if calpain activation occurs, the mechanism does not explain apoptosis resistance.

Hypothesis 3: BAG3-Hsp70 Redistribution

Weak Links

BAG3 specificity is unexplained. BAG3 is highly expressed in muscle and neuronal cells but low in most other cell types. The mechanism for BAG3-dependent protection in motoneurons specifically is plausible, but the hypothesis does not address why other Hsp70 cochaperones (BAG1, HOP) wouldn't serve the same function.

The "redistribution" concept lacks mechanistic detail. How does trehalose cause Hsp70 to re-localize from p62-complexed pools to lysosomal membranes? Trehalose could increase Hsp70 expression, but redistribution requires active transport or competition for binding partners—the hypothesis provides no mechanism.

The p62 paradox. If Hsp70 leaves p62 complexes, p62 is freed to engage autophagy receptors—a reasonable model—but this does not explain apoptosis protection.

Counter-Evidence

• Hsp70 can inhibit autophagy by stabilizing lysosomal membranes or preventing autophagosome-lysosome fusion in some contexts (PMID: 19329990). The switch from inhibitory to protective Hsp70 is not established.
• BAG3 overexpression is associated with proteostasis in muscular diseases, but its role in preventing LMP-induced apoptosis is not demonstrated.

Falsifying Experiments

Revised Confidence: 0.55 (down from 0.68)

The temporal mismatch between stress-gene induction (hours) and LMP (minutes) is a significant weakness. BAG3 involvement is plausible but mechanistically underspecified.

Hypothesis 4: Cathepsin D Substrate Processing

Weak Links

"Substrate X" is undefined. This is the weakest hypothesis by construction. A mechanism that depends on an unidentified substrate cannot be falsified, only confirmed post-hoc.

Cathepsin D release is generally toxic. The cited reference (PMID: 23716583) shows cathepsin D can activate pro-autophagy proteins, but this is context-dependent. Cathepsin D release during LMP is widely considered a pro-death signal.

The dual-function claim is unsupported. Cleaving "inhibitory proteins of apoptosis" while simultaneously activating autophagy requires two unrelated substrates—the hypothesis provides no candidate proteins.

Counter-Evidence

• Cathepsin D release is a well-established trigger of apoptosis via Bid cleavage and caspase activation.
• If trehalose releases cathepsin D, the expected phenotype is cytotoxicity, not autophagy enhancement.

Falsifying Experiments

Revised Confidence: 0.40 (down from 0.58)

While cathepsin D is released in LMP, the hypothesis provides no testable substrate. This is a discovery hypothesis, not a mechanistic one.

Hypothesis 5: TFEB-Induced Lysosome Biogenesis

Weak Links

Temporal mismatch is critical. TFEB activation induces transcription of lysosomal genes (LAMP1, CTSD, ATP6V1H), but transcription, translation, and lysosome biogenesis require hours to days. LMP and autophagy initiation by trehalose likely occur within minutes to hours. How can lysosome biogenesis explain immediate protection?

Threshold argument is circular. The hypothesis states that more lysosomes increase the threshold for apoptosis, but this only explains why more LMP is required—not why the initial LMP is non-toxic. The threshold argument is valid for describing a range of LMP intensity, but does not explain the quality of the response.

Counter-Evidence

• TFEB is activated by calcineurin (Ca²⁺-dependent) and by phosphorylation inhibition via mTORC1 inactivation. Both are rapid responses. However, downstream lysosome biogenesis is slow.
• If lysosome number increases, why is this protective? More lysosomes = more cathepsin mass = higher apoptotic potential if all lysosomes permeabilize.

Falsifying Experiments

Revised Confidence: 0.62 (down from 0.74)

The temporal issue is significant. TFEB activation may be correlative rather than causative. TFEB may be activated by LMP as a survival response, not as the mechanism preventing toxicity.

Hypothesis 6: PI3P Generation at Damaged Lysosomes

Weak Links

The selectivity problem. The hypothesis states that PI3P generation recruits "repair machinery (ESCRT-III) while excluding apoptotic initiators (Apaf-1, procaspase-9)." However, Apaf-1 and caspase-9 are not recruited to damaged lysosomes—they are recruited to the apoptosome after mitochondrial cytochrome c release. This is not a competition for the same recruitment platform. The premise contains a category error.

No mechanism for "excluding" apoptotic initiators. How would PI3P generation specifically exclude Apaf-1? Apaf-1 recruitment requires cytochrome c, which is a mitochondrial event, not lysosomal.

Counter-Evidence

• PI3P generation at damaged lysosomes (via PIK3C3 complex II) is well-established for xenophagy andSalmonella clearance, but its role in general autophagy initiation is contested. Some evidence suggests most autophagosomes form independently of damaged lysosomes.
• ESCRT-III recruitment occurs in parallel with, not instead of, autophagosome formation at damaged lysosomes.

Falsifying Experiments

Feasibility Assessment: Trehalose-LMP Paradox Hypotheses

Executive Summary

Of the seven proposed mechanisms explaining trehalose-induced autophagy without cytotoxicity, three hypotheses warrant prioritized investigation based on mechanistic plausibility and translational tractability. The following assessment addresses druggability, biomarkers, clinical development constraints, safety, and realistic timelines for each viable candidate.

Hypothesis 1: Limited Ca²⁺ Release Without Cathepsin Efflux

Druggability: MODERATE

Target Assessment:
| Target | Tractability | Current Development | Priority |
|--------|--------------|---------------------|----------|
| TRPML1/MCOLN1 | Moderate | Early research; no approved drugs | High |
| Calcineurin/NFAT | High | Cyclosporine A approved; FK506 (tacrolimus) approved | Established |

Key Limitation: The Skeptic correctly identifies that trehalose is not a known TRPML1 agonist. The "selective Ca²⁺ release" mechanism requires either (a) trehalose acting as an uncharacterized channel, or (b) upstream activation of endogenous lysosomal Ca²⁺ channels. Without this mechanistic anchor, druggability is speculative.

Druggability Enhancement Strategy:

• Identify the primary Ca²⁺ release pathway using pharmacological profiling (TRPML1 agonists: ML-SI1; P2X4 blockers; cyclic ADP-ribose modulators)
• Target calcineurin rather than TRPML1—existing immunosuppressants provide proof-of-concept for Ca²⁺-calcineurin axis targeting
• Develop FRET-based high-content screening assay for simultaneous Ca²⁺ release and cathepsin efflux to identify selective small molecules

Biomarkers & Model Systems: MODERATE

Translational Biomarkers:

| Biomarker | Readout | Platform | Confidence |
|-----------|---------|----------|-------------|
| Nuclear TFEB/TFE3 | Immunofluorescence | In vitro high-content | High |
| Lysosomal Ca²⁺ (permeabilized model only) | GCaMP6m-lyso | Live-cell imaging | Moderate |
| Calcineurin activity | NFAT-driven luciferase reporter | Reporter cell lines | Moderate |
| Cathepsin B retention | Magic Red cathepsin B assay | In vitro | High |

Model System Requirements:

• Primary motoneuron cultures (iPSC-derived preferred for human translation)
• Isogenic TFEB knockout lines for mechanism confirmation
• Organoid models (spinal cord or motor cortex) for complex tissue validation

Clinical Development Constraints

Regulatory Pathway:

• If trehalose itself is the therapeutic: 505(b)(1) NDA with existing safety data from non-clinical studies
• If calcineurin modulators are the approach: Significant safety package required (immunosuppression liability)
• TFEB activation biomarkers would require qualification with regulatory agency (FDA/EMA)

Feasibility Resolution: Develop downstream biomarkers of TFEB activation rather than direct target engagement to enable mechanism-based patient stratification.

Safety Assessment: MODERATE CONCERN

Known Risks:

| Risk | Mechanism | Monitoring Strategy |
|------|-----------|---------------------|
| Immunosuppression (calcineurin inhibitors) | NFAT inhibition in immune cells | CBC, lymphocyte subset panels |
| Nephrotoxicity (calcineurin inhibitors) | Afferent arteriole vasoconstriction | eGFR, creatinine, KIM-1 |
| Off-target cathepsin release | Complete LMP | Cytokeratin 18 caspase cleavage fragments (M30/M65 ratio) |

Critical Safety Gap: The therapeutic window depends on "controlled" LMP without complete cathepsin efflux. No validated clinical biomarker exists to confirm this selectivity in patients. This is a significant development risk.

Timeline & Cost: REALISTIC

| Phase | Duration | Estimated Cost | Critical Path |
|-------|----------|----------------|---------------|
| In vitro mechanism validation | 12-18 months | $800K-1.2M | GCaMP6m-lyso sensor development |
| Biomarker assay qualification | 6-9 months | $400-600K | NFAT reporter assay |
| iPSC validation | 12 months | $500K-800K | Isogenic TFEB KO lines |
| IND-enabling studies | 18-24 months | $2-3M | 28-day toxicology in relevant species |
| Total to IND | 3-4 years | $4-6M | — |

Risk Factors: TRPML1 pharmacology is undercharacterized; mechanism may be upstream of direct channel effects.

Hypothesis 5: TFEB-Induced Lysosome Biogenesis

Druggability: MODERATE-HIGH

Target Assessment:

| Target | Tractability | Development Status | Notes |
|--------|--------------|-------------------|-------|
| TFEB/TFE3 (transcription factor) | Low directly | No direct drugs | Undruggable by traditional criteria |
| mTORC1 (indirect TFEB activator) | High | Multiple approved (rapamycin, temsirolimus, everolimus) | Suppresses autophagy at high doses |
| Calcineurin (indirect activator) | High | Cyclosporine A, FK506 approved | Immunosuppression liability |
| V-ATPase (TFEB upstream) | Moderate | Bafilomycin A1 (research only) | Toxicity concerns |

Druggability Enhancement Strategy:

• Prefer indirect targeting via validated pathways (mTORC1, calcineurin) rather than TFEB itself
• Allosteric modulators of TFEB nuclear export (CRM1 inhibitors with narrower therapeutic index)
• Natural compounds (trehalose, genistein, resveratrol) as starting points for structure-activity optimization
• Gene therapy approaches (AAV-mediated TFEB delivery) warrant consideration despite delivery challenges

Biomarkers & Model Systems: HIGH

This hypothesis offers the most tractable biomarker panel:

| Biomarker | Readout | Platform | Status |
|-----------|---------|----------|--------|
| Nuclear TFEB/TFE3 | Immunofluorescence or nuclear extract Western | In vitro/clinical biopsy | Validated |
| LAMP1, CTSD, ATP6V0D1 mRNA | RT-qPCR | Blood mononuclear cells | Clinical grade |
| LysoTracker positivity | Flow cytometry | PBMCs, lymphoblastoid lines | CLIA-available |
| Autophagy flux (LC3-II turnover) | Western blot ± chloroquine | Skin fibroblasts | Established |

Clinical Translation Advantage: Blood-based biomarker strategy (PBMC TFEB target gene expression) is feasible for patient stratification and pharmacodynamic monitoring.

Model System Hierarchy:

Clinical Development Constraints

Regulatory Considerations:

• Patient stratification: TFEB activation status as companion diagnostic—requires CDx qualification
• Endpoints: LC3-II turnover and LAMP1 expression as pharmacodynamic markers (standardization needed)
• Indication-specific requirements: ALS, SMA, and FTD have distinct regulatory frameworks; motor neuron disease focus aligns with source paper

Alternative Clinical Strategy: Trehalose itself as a nutraceutical or off-label therapeutic (already in use for certain storage disorders). This avoids new drug development but limits IP position and dosing control.

Safety Assessment: FAVORABLE PROFILE

Trehalose-Specific Safety:

| Risk | Prevalence | Clinical Monitoring | Mitigation |
|------|------------|---------------------|------------|
| GI intolerance | Dose-dependent | GI symptom diary | Gradual titration |
| Bacterial overgrowth (SIBO) | Low | Gastric symptoms | Lower doses |
| Theoretical metabolic effects | Theoretical | Fasting glucose | Standard monitoring |

If Developing Novel TFEB Activators:

| Risk | Mechanism | Monitoring Strategy |
|------|-----------|---------------------|
| Lysosomal mass accumulation | Excessive biogenesis | LysoTracker imaging |
| Off-target transcription | TFE3 cross-reactivity | Liver/kidney function |
| Proteostasis disruption | Unbalanced flux | UPR markers (XBP1 splicing) |

Safety Advantage: The hypothesis predicts a protective, compensatory response rather than aggressive target engagement—intrinsic safety margin is higher than for most mechanisms.

Timeline & Cost: MODERATE

| Phase | Duration | Estimated Cost | Advantage |
|-------|----------|----------------|-----------|
| Biomarker validation | 6-9 months | $300-500K | Leverages existing assays |
| iPSC efficacy studies | 12 months | $400-600K | Multiple patient lines |
| Preclinical efficacy (mouse) | 12-18 months | $1.5-2.5M | SOD1-G93A established model |
| IND-enabling (trehalose) | 12 months | $1-2M | Existing safety database |
| IND-enabling (novel small molecule) | 24-30 months | $4-6M | Full toxicology package |
| Total (trehalose) | 2.5-3.5 years | $3-5M | Lower cost |
| Total (novel compound) | 4-6 years | $8-15M | Better IP position |

Accelerated Path: Repurposing trehalose as a medical food or dietary supplement for motor neuron disease (off-label) could reach patients within 12-18 months at minimal cost, with post-marketing surveillance generating mechanism-confirming data.

Hypothesis 3: BAG3-Hsp70 Redistribution

Druggability: MODERATE

Target Assessment:

| Target | Tractability | Development Status | Notes |
|--------|--------------|-------------------|-------|
| BAG3 | Low (protein-protein interaction) | Preclinical | Difficult to drug |
| Hsp70 (HSPA1A) | Moderate | Several tool compounds available | Multiple isoforms |
| Hsp70-BAG3 interaction | Low | No established compounds | PPI interface |

Current Compound Landscape:

| Compound | Mechanism | Stage | Limitations |
|----------|-----------|-------|-------------|
| VER-155008 | Hsp70 ATPase inhibitor | Preclinical | Pan-Hsp70; toxicity |
| 2-Phenylethynesulfonamide (PES) | Hsp70/Hsp40 disruptor | Research | Poor solubility |
| Apoptozole | Hsp70 inhibitor | Research | Off-target effects |
| Celastrol | Hsp70 activator | Preclinical | Inflammation, toxicity |

Druggability Enhancement:

• Hsp70 transcriptional upregulation via NRF2 modulators (sulforaphane, bardoxolone) is more tractable than direct PPI targeting
• BAG3 transcriptional induction via heat shock factor (HSF1) activation provides indirect targeting
• Functional mimetics of BAG3-Hsp70 complex (peptidomimetics) are conceptually possible but unvalidated

Biomarkers & Model Systems: MODERATE

Biomarker Panel:

| Biomarker | Readout | Platform | Validation Status |
|-----------|---------|----------|-------------------|
| Hsp70 protein (HSPA1A) | ELISA | Serum, PBMCs | Moderate |
| BAG3 protein | Western/ELISA | Tissue biopsy, PBMCs | Limited |
| Hsp70-BAG3 co-IP | Immunoprecipitation | Cell lysate | Research only |
| Hsp70-p62 co-IP | Immunoprecipitation | Cell lysate | Research only |
| Cytochrome c release | MitoTracker/mCherry-cyto c | Live-cell imaging | Validated |

Translational Biomarker Gap: Clinical application requires a blood-based readout of Hsp70-BAG3 functional complex formation—no validated assay exists. Development of proximity ligation assay (PLA) or AlphaLISA for Hsp70-BAG3 complexes would be required.

Model Systems:

| Model | Utility | Limitation |
|-------|---------|------------|
| BAG3 knockout mice | Mechanism validation | Embryonic lethal (homozygous); heterozygous viable |
| iPSC-derived motoneurons | Disease relevance | BAG3 expression variable |
| Mouse C2C12 myotubes | Robust BAG3 expression | Non-neuronal |